Sino Biological
Progress in Cancer Research by Manufacturing Tough Proteins

Sino Biological is a global leader in the manufacture and supply of affordable, high-quality reagents, including recombinant proteins, antibodies, ELISA kits, and cDNA clones. The company specializes in recombinant production and antibody development that can provide full-service CRO solution to the pharmaceutical, biotechnology, diagnostic industries and academic research institutions.

With proprietary technologies and methodologies, Sino Biological has developed the world’s largest collection of recombinant proteins with a total of 6,500 kinds. 4,500 out of them are manufactured in mammalian expression system that can keep recombinant proteins more closed to nature status. Various kinds of recombinant proteins and even corresponding monoclonal and polyclonal antibodies that represent good targets in the cancer immunotherapy space have been successfully developed, such as immune checkpoints, targets for CAR-T and CAR-NK cell therapies, cytokines and receptors, and viral antigens.

Sino Biological has mastered the art of manufacturing difficult proteins through the years. Not only can Sino Biological produce complex proteins such as immune checkpoint targets with high bioactivity in mammalian cells, but it has every other system in place to meet the diverse needs of customers. To produce challenging targets such as kinases and viral proteins, the company develops them in the baculovirus-insect cell system. By employing new technologies such as cell-free systems, the company can produce a variety of membrane proteins.

Their 1500-liter bioreactor enables Sino Biological to quickly develop gram-level supplies of high-quality proteins and antibodies within a short turnaround time. These proprietary methodologies and infrastructures have helped its clients in creating a huge impact on cancer immunotherapy research and vaccine development.

With proprietary expression platforms and high-throughput and scale-up capabilities, Sino Biological can successfully develop reagents targeting cancer immunotherapy, no matter how difficult the project is.

“Our capability of manufacturing high-quality recombinant proteins, particularly through our proprietary mammalian cell expression platforms, has given our customers the highest opportunity or chances of success when developing a therapy or a vaccine or a diagnostic kit,” says Dr. Rob Burgess, Chief Business Officer of Sino Biological.

Since Sino Biological specializes in manufacturing proteins in mass quantities, it has helped various parties make reagents according to their quality, quantity, and spectrometry requirements. For instance, a client who focuses on developing cancer immunotherapy treatments was interested in obtaining a panel of difficult-to-express biomarkers and corresponding antibodies of a certain type of cancer for research and development. Sino Biological fulfilled its capacity as a contract research organization and succeeded in providing the panel of biomarker proteins and matched antibody pairs validated by ELISA that allow the client to measure the proteins and antibodies contained in biological samples.

Striving to chart similar success stories of valuable discoveries, Sino Biological manufactures tough proteins such as cancer immunotherapy targets to ease the work of researchers developing life-saving cancer treatments and vaccines.